{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-069927","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.592107+00:00","generated_at":"2026-05-24T00:43:42.316994+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities","bullets":["Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).","Additional contingent milestone payments up to $727.5M remain payable under the Merger Agreement.","Acquisition adds OCTEVY, a registrational-stage PET imaging agent for neuroendocrine tumors.","Adds Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO business.","CEO Brian Markison: acquisition enhances capabilities across the radiopharmaceutical value chain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-069927","json":"https://secwatch.observer/filing/0001193125-25-069927.json","markdown":"https://secwatch.observer/filing/0001193125-25-069927.md","text":"https://secwatch.observer/filing/0001193125-25-069927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/0001193125-25-069927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/d905401d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:43:42.316994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd5a21b2a1ec7b8f477a3385c66308dfd209e5fb","claim":"Lantheus Holdings, Inc. completed an acquisition involving Evergreen Theragnostics, Inc. for approximately $275 million in cash (closed 2025-04-01).","evidence_excerpt":"(CDMO) services as well as drug discovery and commercialization of proprietary products. In connection with the closing of the Merger, Lantheus Medical paid approximately $275 million in cash, subject to customary adjustments as set forth in the Merger Agreement, representing the $250 million upfront cash payment and a $25 million milestone payment in respect","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/0001193125-25-069927-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Evergreen Theragnostics, Inc."},{"label":"Consideration","value":"approximately $275 million in cash"},{"label":"Closing","value":"2025-04-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}